Hozzászólás

Gilead vétel: 75,2

MCC vétel: 13,11

"Although Gilead is somewhat infamous on the Street for being a conservative company, they decided to halt their shares prior to releasing earnings after the bell yesterday. And two minutes after the bell, we found out why. Gilead's hepatitis C drug Sovaldi posted global sales of nearly $2.3 billion, making it one of the best drug launches in history. The company also saw strong growth in its HIV franchise, with Stribild growing U.S. sales by 49% year over year. Overall, Gilead reported that revenues increased by 104% year over year, mostly due to the launch of Sovaldi. Shares of this top biotech are up close to 4% in premarket trading presumably based on this earning's beat.

While it would be easy to get hung up on Gilead's new star drug, you should also dig into many of the company's intriguing statements about its clinical program and general business operations. Of particular note, Gilead expects its experimental cancer drug idelalisib to gain FDA approval later this year for two different indications, and the company is deep into planning for the drug's launch as a result. Management also made a point that they will be accelerating their share buyback program in the coming months.

Is Gilead worth keeping tabs on going forward? My view is that Gilead is undervalued after this stellar earnings report--so it's definitely worth checking out. The company is on track to grow annual revenues to around $20 billion this year, meaning that the stock is trading at a forward price to earnings ratio of less than 12. That said, management still didn't feel comfortable providing annual guidance for Sovaldi. As such, the market may remain unconvinced that Gilead is a bargain, despite what I view as some good evidence to the contrary."